Urogen Pharma Ltd (NASDAQ:URGN)
| 5.65 Delayed Data As of May 20 |  +0.14 / +2.54%Today’s Change | 5.25 Today|||52-Week Range 19.66 | -40.59% Year-to-Date |
Latest URGN News | Press Releases
| Urogen Pharma (URGN) Reports Q1 Loss, Misses Revenue Estimates May 10 / Zacks.com - Paid Partner Content | Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates May 09 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 5.51 |
| Today’s open | 5.41 |
| Day’s range | 5.25 - 5.65 |
| Volume | 5,702 |
| Average volume (3 months) | 142,289 |
| Market cap | $137.5M |
Data as of 4:04pm ET, 05/20/2022
Growth & Valuation
| Earnings growth (last year) | +15.93% |
| Earnings growth (this year) | +9.88% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +307.17% |
| P/E ratio | NM |
| Price/Sales | 4.42 |
| Price/Book | 16.18 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CRMDCorMedix Inc | -0.11 | -3.15% |
| INMBINmune Bio Inc | -0.07 | -0.94% |
| NMTR9 Meters Biopharma I... | +0.04 | +9.49% |
| PIRSPieris Pharmaceutica... | +0.01 | +0.56% |
Data as of 4:05pm ET, 05/20/2022
Financials
| Next reporting date | August 15, 2022 |
| EPS forecast (this quarter) | -$1.23 |
| Annual revenue (last year) | $48.0M |
| Annual profit (last year) | -$110.8M |
| Net profit margin | -230.67% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Princeton, New Jersey |
Forecasts
